email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2644-1373

LOJ Pharmacology & Clinical Research

Case Report(ISSN: 2644-1373)

Complex and Severe Amiodarone-Induced Pleuro- Pulmonary Toxicity

Volume 1 - Issue 2

Salem Bouomrani S1,2*, Salsabil Dabboussi3,4, Nesrine Regaïeg1, Nesrine Begacem1, Maher Béji1,4

  • Author Information Open or Close
    • 1Department of Internal medicine. Military Hospital of Gabes, Tunisia
    • 2Sfax Faculty of Medicine. University of Sfax, Tunisia
    • 3Department of Pneumology. Military Hospital of Tunis, Tunisia
    • 4Tunis Faculty of Medicine. Tunis El Manar University, Tunisia

    *Corresponding author: Salem Bouomrani, Department of Internal medicine, Military Hospital of Gabes, Tunisia

Received: September 26, 2018;   Published: October 03, 2018

DOI: 10.32474/LOJPCR.2018.01.000106

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Introduction: Pulmonary complications related to amiodarone have become exceptional with the doses currently used; their frequency is estimated at 1.6-2%. Acute or subacute pneumonia is the most classic manifestation. Pleural involvement under amiodarone is exceptional and unusual. We report an original observation of triple toxicity to amiodarone with concomitant pulmonary parenchymal, pleural and hepatic involvement and which was spontaneously resolved.

Case Report: 71-years-old patient, hypertensive and diabetic type 2, without degenerative complications, treated with amiodarone for four years for atrial fibrillation, was hospitalized because of severe acute pneumopathy evolving for ten days. Biology revealed moderate cytolytic hepatitis (ASAT at 130 IU/l and ALAT at 243 IU/l) without cholestasis or liver failure. Chest X-ray and thoracic CT showed bilateral and diffuse interstitial infiltrates, severe bilateral pneumonitis of both upper lobes, diffuse patchy infiltrates and ground–glass opacity, and bilateral pleural effusion. Abdominal ultrasound and CT showed moderate homogeneous and hyperdense hepatomegaly without focal lesions. The infectious, immunological, and tumoral investigations were negative. The hypothesis of drug toxicity was retained, and the evolution was rapidly favorable after stopping amiodarone with disappearance of respiratory complaints, normalization of liver tests, and progressive radiological cleansing. Chest radiography and thoracic CT scan were substantially normal at six months.

Conclusion: Amiodarone-induced complex pulmonary toxicity with parenchymal and pleural involvement remains exceptional and not well known by clinicians. Regular clinical and radiological monitoring are recommended to detect and manage them in time, and improve the prognosis given the risk of irreversible fibrosis evaluated at 5-7% of cases.

Keywords: Amiodarone; Pneumonitis; Pleuritis; Amiodarone Pulmonary Toxicity; Hepatitis; Toxicity

Abbreviations: ASAT: Aspartate Aminotransferase; ALAT: Alanine Aminotransferase; Ana: Antinuclear Antibodies; P-Anca: Perinuclear Antineutrophil Cytoplasmic Antibodies; C-Anca: Cytoplasmic Antineutrophil Cytoplasmic Antibodies; Anti-Lkm1: Anti- Liver/Kidney Microsome Antibodies; Anti-M2: Anti-Mitochondrial Antibodies M2 Subtype

Abstract| Introduction| Case Report| Discussion| Conclusion| References|

https://www.high-endrolex.com/21